Remove Drugs Remove FDA Approval Remove Recombinant DNA Technology
article thumbnail

Amivantamab by Johnson & Johnson for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Amivantamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

article thumbnail

What is the Difference Between Biologics and Biosimilars?

Pharma Packaging Solutions

Biologics are drug products that are manufactured using materials from living sources. There are a few common types of biologics, including extracted (taken directly from a living system), semi-synthesized (produced with recombinant DNA technology), vaccines, and gene therapies. Let’s talk about it. What are Biologics?